198 related articles for article (PubMed ID: 30614135)
1. Rotavirus VP6 as a potential vaccine candidate.
Afchangi A; Jalilvand S; Mohajel N; Marashi SM; Shoja Z
Rev Med Virol; 2019 Mar; 29(2):e2027. PubMed ID: 30614135
[TBL] [Abstract][Full Text] [Related]
2. Rotavirus VP6 preparations as a non-replicating vaccine candidates.
Jalilvand S; Marashi SM; Shoja Z
Vaccine; 2015 Jun; 33(29):3281-7. PubMed ID: 26021725
[TBL] [Abstract][Full Text] [Related]
3. Targeting of rotavirus VP6 to DEC-205 induces protection against the infection in mice.
Badillo-Godinez O; Gutierrez-Xicotencatl L; Plett-Torres T; Pedroza-Saavedra A; Gonzalez-Jaimes A; Chihu-Amparan L; Maldonado-Gama M; Espino-Solis G; Bonifaz LC; Esquivel-Guadarrama F
Vaccine; 2015 Aug; 33(35):4228-37. PubMed ID: 25850020
[TBL] [Abstract][Full Text] [Related]
4. Engineering and expression of a human rotavirus candidate vaccine in Nicotiana benthamiana.
Pêra FF; Mutepfa DL; Khan AM; Els JH; Mbewana S; van Dijk AA; Rybicki EP; Hitzeroth II
Virol J; 2015 Dec; 12():205. PubMed ID: 26626122
[TBL] [Abstract][Full Text] [Related]
5. VP6: A candidate rotavirus vaccine.
Ward RL; McNeal MM
J Infect Dis; 2010 Sep; 202 Suppl():S101-7. PubMed ID: 20684688
[TBL] [Abstract][Full Text] [Related]
6. Protection against live rotavirus challenge in mice induced by parenteral and mucosal delivery of VP6 subunit rotavirus vaccine.
Lappalainen S; Pastor AR; Malm M; López-Guerrero V; Esquivel-Guadarrama F; Palomares LA; Vesikari T; Blazevic V
Arch Virol; 2015 Aug; 160(8):2075-8. PubMed ID: 26016444
[TBL] [Abstract][Full Text] [Related]
7. Rotavirus vaccination and infection induce VP6-specific IgA responses.
Lappalainen S; Blazevic V; Malm M; Vesikari T
J Med Virol; 2017 Feb; 89(2):239-245. PubMed ID: 27431308
[TBL] [Abstract][Full Text] [Related]
8. Immunization of Mice by Rotavirus NSP4-VP6 Fusion Protein Elicited Stronger Responses Compared to VP6 Alone.
Afchangi A; Arashkia A; Shahosseini Z; Jalilvand S; Marashi SM; Roohvand F; Mohajel N; Shoja Z
Viral Immunol; 2018 Apr; 31(3):233-241. PubMed ID: 29185875
[TBL] [Abstract][Full Text] [Related]
9. Detection of diarrhoea associated rotavirus and co-infection with diarrhoeagenic pathogens in the Littoral region of Cameroon using ELISA, RT-PCR and Luminex xTAG GPP assays.
Ghapoutsa RN; Boda M; Gautam R; Ndze VN; Mugyia AE; Etoa FX; Bowen MD; Esona MD
BMC Infect Dis; 2021 Jun; 21(1):614. PubMed ID: 34182936
[TBL] [Abstract][Full Text] [Related]
10. Comparative immunogenicity in mice of rotavirus VP6 tubular structures and virus-like particles.
Lappalainen S; Tamminen K; Vesikari T; Blazevic V
Hum Vaccin Immunother; 2013 Sep; 9(9):1991-2001. PubMed ID: 23777748
[TBL] [Abstract][Full Text] [Related]
11. Immune responses elicited against rotavirus middle layer protein VP6 inhibit viral replication in vitro and in vivo.
Lappalainen S; Pastor AR; Tamminen K; López-Guerrero V; Esquivel-Guadarrama F; Palomares LA; Vesikari T; Blazevic V
Hum Vaccin Immunother; 2014; 10(7):2039-47. PubMed ID: 25424814
[TBL] [Abstract][Full Text] [Related]
12. The assembly conformation of rotavirus VP6 determines its protective efficacy against rotavirus challenge in mice.
Pastor AR; Rodríguez-Limas WA; Contreras MA; Esquivel E; Esquivel-Guadarrama F; Ramírez OT; Palomares LA
Vaccine; 2014 May; 32(24):2874-7. PubMed ID: 24583002
[TBL] [Abstract][Full Text] [Related]
13. Self-assembling Rotavirus VP6 Nanoparticle Vaccines Expressed in Escherichia coli Elicit Systemic and Mucosal Responses in Mice.
Li Z; Cui K; Huang K; Liu F; Shi D; Liu Q
Protein Pept Lett; 2019; 26(12):904-909. PubMed ID: 31429685
[TBL] [Abstract][Full Text] [Related]
14. Molecular cloning and immunogenicity evaluation of rotavirus structural proteins as candidate vaccine.
El-Senousy WM; Shahein YE; Barakat AB; Ghanem HE; El-Hakim AE; Ameen SM
Int J Biol Macromol; 2013 Aug; 59():67-71. PubMed ID: 23588003
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of VP6 immunogenicity and protective efficacy against rotavirus by VP2 in a genetic immunization.
Lopez-Guerrero DV; Arias N; Gutierrez-Xicotencatl L; Chihu-Amparan L; González A; Pedroza-Saavedra A; Rosas-Salgado G; Villegas-Garcia JC; Badillo-Godinez O; Fernandez G; Lopez S; Esquivel-Guadarrama F
Vaccine; 2018 May; 36(22):3072-3078. PubMed ID: 28465094
[TBL] [Abstract][Full Text] [Related]
16. Rotavirus capsid VP6 tubular and spherical nanostructures act as local adjuvants when co-delivered with norovirus VLPs.
Malm M; Heinimäki S; Vesikari T; Blazevic V
Clin Exp Immunol; 2017 Sep; 189(3):331-341. PubMed ID: 28407442
[TBL] [Abstract][Full Text] [Related]
17. Intradermal and intranasal immunizations with oligomeric middle layer rotavirus VP6 induce Th1, Th2 and Th17 T cell subsets and CD4
Heinimäki S; Malm M; Vesikari T; Blazevic V
Antiviral Res; 2018 Sep; 157():1-8. PubMed ID: 29935205
[TBL] [Abstract][Full Text] [Related]
18. Influence of potential protective mechanisms on the development of live rotavirus vaccines.
Ward RL; Clark HF; Offit PA
J Infect Dis; 2010 Sep; 202 Suppl():S72-9. PubMed ID: 20684721
[TBL] [Abstract][Full Text] [Related]
19. Improved characteristics and protective efficacy in an animal model of E. coli-derived recombinant double-layered rotavirus virus-like particles.
Li T; Lin H; Zhang Y; Li M; Wang D; Che Y; Zhu Y; Li S; Zhang J; Ge S; Zhao Q; Xia N
Vaccine; 2014 Apr; 32(17):1921-31. PubMed ID: 24530406
[TBL] [Abstract][Full Text] [Related]
20. Sequence and phylogenetic analyses of human rotavirus strains: comparison of VP7 and VP8(∗) antigenic epitopes between Tunisian and vaccine strains before national rotavirus vaccine introduction.
Mouna BH; Hamida-Rebaï MB; Heylen E; Zeller M; Moussa A; Kacem S; Van Ranst M; Matthijnssens J; Trabelsi A
Infect Genet Evol; 2013 Aug; 18():132-44. PubMed ID: 23684631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
